Home » Thought Leadership

Thought Leadership

Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 124 posts
Tessa Malone CBPartners 2020 Summer Analyst
September 29, 2020 | Culture Blog

My Experience as a Summer Analyst: CBPartners’ Summer Internship Program

Tessa Malone details her experience as a Summer Analyst at CBPartners. Find out why she applied for the summer internship program and how CBPartners stood out as a top global healthcare strategy consulting firm.

September 22, 2020 | Blogs

CAR-Ts: Barriers and Opportunities for the Migration into Earlier Lines of Therapy in the USA

CAR-Ts offer a significant clinical benefit for patients, however their full potential is currently limited by later line use at sites that are mostly academic centers, combined with significant logistical barriers. In CBPartners’ latest thought leadership article, our healthcare consultants look further into these barriers before assessing the opportunities that could bring CAR-Ts into earlier lines of treatment across oncology.

September 17, 2020 | Blogs

Hitting the Mark: Lessons Learned From Blockbuster Drugs That Missed or Exceeded Analyst Expectations

Pharmaceutical products can both exceed and fall short of blockbuster sales expectations by considerable margins which can be a result of a number of reasons. Some of these include the value of first-to-market dynamics, supporting real-world evidence to gain a competitive edge, and continual investment in trials for follow-on indications to improve life cycle management.

Decorative image of blog post depicting biopharma
September 8, 2020 | Blogs

How Do Companies Spend the Revenue Generated from Blockbuster Drugs? A Closer Look at Vertex and Gilead

Blockbuster drugs can generate billions of dollars for pharmaceutical manufacturers, but what can be learned from the investment strategies that GILEAD and VERTEX pursued from the revenue that they generated from SOVALDI and ORKAMBI respectively?